CN102988949B - Medicament for treating rhinitis - Google Patents
Medicament for treating rhinitis Download PDFInfo
- Publication number
- CN102988949B CN102988949B CN201210534892.4A CN201210534892A CN102988949B CN 102988949 B CN102988949 B CN 102988949B CN 201210534892 A CN201210534892 A CN 201210534892A CN 102988949 B CN102988949 B CN 102988949B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- medicament
- treatment
- rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating rhinitis. The medicament is prepared from the following materials, by weight: 10-20 parts of dragonhead, 5-15 parts of Potentilla, 1-15 parts of Anemarrhena, 1-10 parts of Cacumen Platycladi, 1-5 parts of radix sileris, 5-10 parts of Onychium japonicum, 5-10 parts of dried ginger, 3-8 parts of madder, 5-10 parts of Selaginella tamariscina, 10-20 parts of Adonis amurensis, 10-30 parts of Chinese Azalea Flower, 1-20 parts of herba lycopi, 1-10 parts of asarum, 10-20 parts of Amomum tsao-ko and 1-10 parts of immature orange fruit. The medicament for treating rhinitis has characteristics of low cost, easy preparation, little toxic and side effect, and significant efficacy.
Description
Technical field
The present invention relates to otorhinolaryngology field, specifically, relate to a kind of medicament for the treatment of rhinitis.
Background technology
Rhinitis cardinal symptom is break out nasal obstruction, rhinocnesmus, sneeze, snivel etc. of paroxysmal, or oral cavity, pharyngeal cavity, eye, ear part have an itch, or with olfactory disorder, or with allergic sinusitis, or headache, giddy, during secondary infection, can there is yellow thick nasal discharge, or with bronchial asthma.Though western medicine can be alleviated clinical symptoms, curative effect shakiness in various degree at present.Therefore, in the urgent need to finding a kind of medicament for the treatment of rhinitis.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of rhinitis.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of rhinitis, it is to be made by the material of following weight proportioning: Herba Dracocephali Integrifolii 10-20 part, Herba Potentillae Chinensis 5-15 part, Rhizoma Anemarrhenae 1-15 part, Cacumen Platycladi 1-10 part, Radix Saposhnikoviae 1-5 part, Herba Pteridis creticae 5-10 part, Rhizoma Zingiberis 5-10 part, Radix Rubiae 3-8 part, Herba Selaginellae 5-10 part, Amur Adonis Herb 10-20 part, Flos Rhododendri Mollis 10-30 part, Herba Lycopi 1-20 part, Herba Asari 1-10 part, Fructus Tsaoko 10-20 part and Fructus Aurantii Immaturus 1-10 part.
Preferably, the medicament for the treatment of rhinitis of the present invention is to be made by the material of following weight proportioning: 4 parts of 15 parts of Herba Dracocephali Integrifoliis, 10 parts of Herba Potentillae Chinensis, 10 parts of the Rhizoma Anemarrhenaes, 5 parts of Cacumen Platycladis, 3 parts of Radix Saposhnikoviaes, 8 parts of Herba Pteridis creticae, 7 parts of Rhizoma Zingiberiss, 6 parts, Radix Rubiae, 7 parts of Herba Selaginellaes, 16 parts of Amur Adonis Herbs, 22 parts of Flos Rhododendri Mollis, 13 parts of Herba Lycopi, 5 parts of Herba Asaris, 13 parts of Fructus Tsaokos and Fructus Aurantii Immaturuss.
Preferably, medicament of the present invention is tablet, buccal tablet, instant or decoction.
The medicament for the treatment of rhinitis of the present invention has the advantages that cost is low, preparation is easy, toxic and side effects is little, curative effect is showing.
The specific embodiment
Embodiment 1: the preparation of decoction of the present invention
Claim 40 grams of 150 grams of Herba Dracocephali Integrifoliis, 100 grams of Herba Potentillae Chinensis, 100 grams of the Rhizoma Anemarrhenaes, 50 grams of Cacumen Platycladis, 30 grams of Radix Saposhnikoviaes, 80 grams of Herba Pteridis creticae, 70 grams of Rhizoma Zingiberiss, 60 grams, Radix Rubiae, 70 grams of Herba Selaginellaes, 160 grams of Amur Adonis Herbs, 220 grams of Flos Rhododendri Mollis, 130 grams of Herba Lycopi, 50 grams of Herba Asaris, 130 grams of Fructus Tsaokos and Fructus Aurantii Immaturuss, add 2500 milliliters, water, be placed in the flask of sealing, under the water-bath of 80 ℃, heat 4 hours, filter, collect filtrate and get final product.
Experimental example
Diagnostic criteria
The diagnostic criteria of recommending in the principle of diagnosis and treatment of the Chinese ear,nose & throat-head and neck surgical magazine of reference editorial board, hals,Nasen und Ohrenheilkunde branch of Chinese Medical Association allergic rhinitis and suggested design (Lanzhou in 2004) is in conjunction with traditional classification method.The course of disease at least 1 year; Perennial onset, has in rhinocnesmus, sneeze, nasal discharge and 4 symptoms of nasal obstruction at least 3, and the number of days accumulative total of falling ill in 1 year exceedes 6 months, and in 1 day, disease time accumulation exceedes 0.5-1h.Allergen skin test is positive, and at least one is (++) or more than (++).
Inclusive criteria
1. meet diagnostic criteria.2. age 18-65 one full year of life, men and women does not limit.3. this treatment is not accepted any antianaphylactic treatment in first 2 weeks.4. patient's informed consent.
Choose rhinitis patient's 57 examples that meet above-mentioned standard, be divided into treatment group 29 examples, matched group 28 examples, two groups are compared there was no significant difference (P > 0.05) in sides such as sex, age, the course of disease, state of an illness scorings, have comparability.
Decoction prepared by the oral embodiment 1 for the treatment of group, every twice-daily,, treats 2 weeks by each 50 milliliters.The oral loratadine tablet of matched group (Shanghai Schering Plough pharmaceutical Co. Ltd), once a day, each 10mg, treats 2 weeks.
Lab testing: before allergic rhinitis patients treatment, extract respectively patient's limosis vein blood liquid 2mL after treatment, after centrifugation, retain its serum, leave in-20 ℃ of refrigerators to be measured.Adopt DASELISA immunoabsorption (ELISA) to measure serum interleukin (IL-2 and IL-4) content, operating procedure is carried out in strict accordance with test kit description.
Safety index is observed: general health check-up project has body temperature, breathing, arteries and veins, blood pressure.Before and after treatment, survey blood, urine, stool routine and liver function, renal function each 1 time.
Criterion of therapeutical effect
With reference to the efficacy assessment standard of recommending in the principle of diagnosis and treatment of Chinese ear,nose & throat-head and neck surgical magazine editorial board, hals,Nasen und Ohrenheilkunde branch of Chinese Medical Association allergic rhinitis and suggested design (Lanzhou in 2004), according to the percentage rate of summation that before and after treatment, sings and symptoms is scored, improvement by following formula calculative determination curative effect: (before treatment after total score-treatment total score) front total score × 100% of/treatment.> 65% is effective, >=25% and≤65% be effectively ,≤25% is invalid.
Therapeutic outcome
In treatment group 29 examples, effective 10 examples, effective 16 examples, invalid 3 examples, total effective rate 89.7%; In matched group 28 examples, effective 5 examples, effective 17 examples, invalid 6 examples, total effective rate 78.6%.Two groups of curative effects relatively have significant difference P < 0.05, and treatment group curative effect is better than matched group.
Before and after two groups of treatments, detect Serum Indexes comparison, in Table 1.Before two groups of treatments, compare the horizontal there was no significant difference of patients serum IL-2, IL-4 (P > 0.1).After two groups of treatments, patient serum il-4 all decline, IL-2 all raises, with treat before relatively have significant differences (P < 0.01); After treatment, between group, compare, treatment group is obviously better than matched group (P < 0.01).
Before and after table 1 liang group treatment, serum il-4, IL-2 value are relatively
ρ/pgmL
-1
With Δ P < 0.01 relatively before treatment, with ★ P < 0.05 relatively after treatment of control group, with relatively * P < 0.01 of matched group difference
Safety analysis
In observation, do not occur serious adverse reaction, blood, urine, stool routine and hepatic and renal function inspection that treatment finishes rear treatment group and matched group patient are showed no extremely.
Claims (2)
1. treat a medicament for rhinitis, it is characterized in that it is to be made by the material of following weight proportioning: Herba Dracocephali Integrifolii 10-20 part, Herba Potentillae Chinensis 5-15 part, Rhizoma Anemarrhenae 1-15 part, Cacumen Platycladi 1-10 part, Radix Saposhnikoviae 1-5 part, Herba Pteridis creticae 5-10 part, Rhizoma Zingiberis 5-10 part, Radix Rubiae 3-8 part, Herba Selaginellae 5-10 part, Amur Adonis Herb 10-20 part, Flos Rhododendri Mollis 10-30 part, Herba Lycopi 1-20 part, Herba Asari 1-10 part, Fructus Tsaoko 10-20 part and Fructus Aurantii Immaturus 1-10 part.
2. the medicament for the treatment of rhinitis according to claim 1, is characterized in that it is to be made by the material of following weight proportioning: 4 parts of 15 parts of Herba Dracocephali Integrifoliis, 10 parts of Herba Potentillae Chinensis, 10 parts of the Rhizoma Anemarrhenaes, 5 parts of Cacumen Platycladis, 3 parts of Radix Saposhnikoviaes, 8 parts of Herba Pteridis creticae, 7 parts of Rhizoma Zingiberiss, 6 parts, Radix Rubiae, 7 parts of Herba Selaginellaes, 16 parts of Amur Adonis Herbs, 22 parts of Flos Rhododendri Mollis, 13 parts of Herba Lycopi, 5 parts of Herba Asaris, 13 parts of Fructus Tsaokos and Fructus Aurantii Immaturuss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210534892.4A CN102988949B (en) | 2012-12-06 | 2012-12-06 | Medicament for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210534892.4A CN102988949B (en) | 2012-12-06 | 2012-12-06 | Medicament for treating rhinitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102988949A CN102988949A (en) | 2013-03-27 |
| CN102988949B true CN102988949B (en) | 2014-04-16 |
Family
ID=47918386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210534892.4A Expired - Fee Related CN102988949B (en) | 2012-12-06 | 2012-12-06 | Medicament for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988949B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104645286A (en) * | 2014-06-16 | 2015-05-27 | 刘波 | Medicinal preparation for treating rhinitis |
| CN105943609A (en) * | 2016-06-20 | 2016-09-21 | 东莞市乐堂医疗投资有限公司 | External-use traditional Chinese medicine preparation for treating rhinitis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879791A (en) * | 2006-04-28 | 2006-12-20 | 白安福 | A nasal drop for treating rhinitis and method for preparing same |
-
2012
- 2012-12-06 CN CN201210534892.4A patent/CN102988949B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879791A (en) * | 2006-04-28 | 2006-12-20 | 白安福 | A nasal drop for treating rhinitis and method for preparing same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102988949A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11986553B2 (en) | Multi-component injection | |
| NZ220295A (en) | Nerium extracts and medicaments for treating and detecting cell-proliferative disease | |
| CN107714805B (en) | Application of thoroughfare bitter orange extract in preparation of traditional Chinese medicine preparation or functional food | |
| CN103933203B (en) | A kind of compound recipe Hematogenesis capsule being used for the treatment of aplastic anemia and preparation method thereof | |
| CN103784933B (en) | Recurrent oral ulceration falls apart | |
| CN103230506B (en) | Bone-setting medicament | |
| CN102988949B (en) | Medicament for treating rhinitis | |
| CN107050014A (en) | Artesunate as anti-leukocythemia tumour medicine application | |
| CN102813747B (en) | Traditional Chinese medicine for treating systemic lupus erythematosus | |
| CN117137998B (en) | Pharmaceutical composition for treating yin deficiency damp-heat type viral infection and pulmonary nodule, preparation and application thereof | |
| CN101278957A (en) | Application of extract of Gynura Divaricata in anti-cancer medicine | |
| Leong et al. | Shengmai San: a modern medicine perspective on its remedial effects on Qi and Yin deficiency syndrome in Chinese medicine | |
| CN106309758B (en) | Pharmaceutical composition for resisting gastrointestinal cancer | |
| CN107837384A (en) | A kind of Chinese medicine composition for treating hand-foot-and-mouth disease | |
| Wu et al. | Burdock essence promotes gastrointestinal mucosal repair in ulcer patients | |
| CN104586866A (en) | A pharmaceutical composition for treating cerebrovascular diseases | |
| Uttamani et al. | Therapeutic Modalities in the management of COVID-19: A worldwide landscape | |
| CN102488825B (en) | Traditional Chinese medicine composition for treating beriberoid pyretic arthralgia and application of traditional Chinese medicine composition | |
| CN109893500A (en) | A kind of compound multicomponent injection | |
| Wang et al. | Gleditsiae sinensis fructus Pills combined with Jujubae fructus attenuate chronic bronchitis via regulation of AGE-RAGE signaling pathway | |
| CN106963822A (en) | Prevent and treat Chinese medicine composition of infectious bronchitis of chicken and its preparation method and application | |
| CN106377583A (en) | Gansu genuine medicinal material radix aconiti penduli processing technology and quality detection method of Gansu genuine medicinal material radix aconiti penduli | |
| Bałan et al. | Experimental immunology the effect of multi-component herbal remedy Pervivo on cellular immunity and tumor angiogenesis in mice | |
| CN116407533A (en) | Application of sesquiterpenoids lolide in preparing medicament for treating viral pneumonia | |
| Rohmawaty et al. | Ciplukan (Physalis Angulata Linn.) Extract Potential on High-Fat Diet-Induced Non-alcoholic Fatty Liver Disease (NAFLD) for Liver Anti-Fibrotic Drug Development. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20151206 |
|
| EXPY | Termination of patent right or utility model |